Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib for moderate hospitalized COVID-19
2022-500363-12-00Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bemcentinib with Placebo (2 arms). Primary endpoint: Disease state on the 11-point WHO progression scale at Day 8. Started Jul 2022; status: completed.
02
Drugs
bemcentinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-500363-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500363-12-00.